NL2026445B1 - Method for performing a plurality of diagnostic tests - Google Patents

Method for performing a plurality of diagnostic tests Download PDF

Info

Publication number
NL2026445B1
NL2026445B1 NL2026445A NL2026445A NL2026445B1 NL 2026445 B1 NL2026445 B1 NL 2026445B1 NL 2026445 A NL2026445 A NL 2026445A NL 2026445 A NL2026445 A NL 2026445A NL 2026445 B1 NL2026445 B1 NL 2026445B1
Authority
NL
Netherlands
Prior art keywords
test sample
test
laboratory
prevalence
sample
Prior art date
Application number
NL2026445A
Other languages
Dutch (nl)
Inventor
Bakker Ed
Henricus Gerardus Maria Koppelman Marcus
Wilhelmus Maria Van Weert Antonius
Geert Ten Oever Albert
Original Assignee
Sanquin Diagnostiek B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin Diagnostiek B V filed Critical Sanquin Diagnostiek B V
Priority to NL2026445A priority Critical patent/NL2026445B1/en
Application granted granted Critical
Publication of NL2026445B1 publication Critical patent/NL2026445B1/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/80—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)

Abstract

A method for performing a plurality of diagnostic tests is provided, comprising obtaining a first test sample from a first patient, obtaining a second test sample from a second patient, obtaining, from a prevalence database comprising prevalence factor data, a first prevalence factor for the first test sample and a second prevalence factor for the second test sample, and, based on the first prevalence factor and the second prevalence factor, one of testing the first test sample and the second test sample individually or combining the two test samples into a third test sample and testing the third test sample as a pooled sample.

Description

P128277NL00 Title: Method for performing a plurality of diagnostic tests
TECHNICAL FIELD The aspects and embodiments thereof relate to methods for performing a plurality of diagnostic tests.
BACKGROUND Every day, diagnostic tests are performed on test samples, for example to determine whether a patient is infected with a particular virus such as coronavirus SARS-CoV2. Each test requires lab capacity and particular test materials to be performed properly. When a large number of tests has to be performed, and in particular when test materials and/or lab capacity is scarce, a large amount of time may lapse before the outcome of the diagnostic test can be established. Especially when testing for contagious diseases, a quick outcome of the diagnostic test is preferred to be able to quarantine patients whose test results are positive.
SUMMARY It is preferred to provide a method for performing a plurality of diagnostic tests which may require less lab capacity and/or less test materials and/or allows for less time to lapse before the outcome of the diagnostic tests can be established. A method is provided for performing a plurality of diagnostic tests. The method comprises obtaining a first test sample from a first patient, obtaining a second test sample from a second patient, obtaining, from a prevalence database comprising prevalence factor data, a first prevalence factor for the first test sample and a second prevalence factor for the second test sample; and based on the first prevalence factor and the second prevalence factor, one of testing the first test sample and the second test sample individually or combining the two test samples into a third test sample and testing the third test sample as a pooled sample.
When the first test sample and the second test sample are tested individually, as an option, the method may further comprise determining which of the first test sample and the second test sample to test first based on at least one of the first prevalence factor and the second first prevalence factor.
It may be more economical to pool samples together, because as such it may be possible to test a number of test samples using less resources compared to testing each individual test sample separately. For example, 2, 4, 6 or even more samples may be pooled together. The same type of diagnostic test may be ran on a pooled sample as on an individual sample.
If the result of the diagnostic test on the pooled sample is negative, this may be indicative of each individual test sample in the pooled sample to be negative as well. If the result of the diagnostic test on the pooled sample is positive, more tests may have to be conducted to evaluate which of the individual test samples were positive. In particular, only one positive individual test sample may result in the diagnostic test on the pooled sample to result 1n a positive outcome.
The method may further comprise obtaining any additional number of test samples, and obtaining any number of additional prevalence factors for the additional test samples. As such, based on the first prevalence factor, the second prevalence factor, and any number of additional prevalence factors, it may be determined whether to pool two or more of the test samples and/or in which order to test the test samples.
A test sample may comprise any material on which a diagnostic test may be performed, for example blood, urine, saliva, nasal secretions any other bodily fluid or any combination thereof. Obtaining a test sample may imply physically obtaining the sample from a human or animal patient, for example using a needle or nasopharyngeal swab. Obtaining a test sample may otherwise imply receiving a previously obtained test sample, for example provided in a test tube or other container. A diagnostic test may be performed on a test sample. The diagnostic test may result in a test result which may for example be positive of negative for a particular condition. Such a condition may for example be indicative for the presence of a virus in the test sample. For example, using a PCR (polymerase chain reaction) diagnostic test to test for a contamination with SARS-CoV 2, a test sample may turn out positive if SARS-CoV 2 RNA is present in the test sample above a certain threshold.
The prevalence database comprises prevalence factor data. The prevalence of a particular condition may be defined as the proportion of a particular population found to be affected by said medical condition, for example within a particular geographical area. The prevalence factor data comprises a set of prevalence factors with which a test sample may be associated. A prevalence factor may for example be a particular percentage or range of percentages and may be expressed as the percentage or range of percentages or by using an associated descriptor such as “low”, “medium”, “high” and “max”.
As an option, the prevalence database may be stored on an electronic memory device, and the obtaining of the first prevalence factor and the second prevalence factor may be performed by an electronic computer device.
The electronic memory device on which the prevalence database is stored may for example be a flash drive, hard disk drive or solid state drive.
The electronic memory device may for example be accessible via the internet or an intranet, and may as such be a so-called cloud database.
For example, a user may use an electronic computer device such as a laptop, PC, smartphone or tablet to query the database for obtaining prevalence data.
When the first prevalence factor and the second prevalence factor are both below a predetermined prevalence factor threshold, the two test samples may be combined into a third test sample and the third test sample may be tested as a pooled sample. In further embodiments of the method, any number of additional test samples may be pooled into the third test sample when their respective prevalence factors are also below the predetermined prevalence factor threshold.
For example, based on statistical models, a prevalence factor threshold may be determined, which threshold may be used to determine whether two or more test samples should be combined into a pooled sample. For example, if the prevalence factor threshold is “medium”, and for both the first test sample and the second test sample a prevalence factor “low” is obtained from the prevalence database, it may be decided to combine the first test sample and the second test sample into a pooled sample.
As a further option, embodiments of the method may further comprise updating the prevalence database based on the test results of the first test sample and/or the second test sample and/or the third test sample. As such, the prevalence factor data may be updated based on newly obtained diagnostic test results. Updates may for example be made after obtaining one or more diagnostic test results and/or every certain amount of time such as hourly, daily or weekly.
In embodiments, the first test sample may be obtained at a first collection site, the second test sample may be obtained at a second collection site, and the prevalence factor data may comprise prevalence data for the first collection site and the second collection site.
A collection site may be a geographical location, such as a particular town or even a particular address. Different test samples may be obtained at different collection sites. Prevalence of a particular medical condition may be expressed for certain regions, and the prevalence of different regions may differ. With contagious diseases for example caused by viruses,
prevalence may differ between adjacent regions. Hence, the prevalence data may comprise prevalence factors for particular collection sites and/or regions. A region may for example be a country, province, city, neighbourhood, or any other type of geographical region.
5 A plurality of collection sites may be located at a collection hub at a single geographical location, such as a hospital, sports arena, or any other location. Different collection sites of a single collection hub may be associated with a different prevalence factor.
For example, a first collection site at a first collection hub may be arranged to obtain test samples from patients with additional prevalence factors, such as patients who had close contact with positively tested patients, patients with a high-risk profession such as medical personnel, patients exhibiting particular medical symptoms, persons who potentially could have been infected by positive patients from whom they did not know they were positive, hence persons who are asymptomatic but at risk of being infected, persons who have been traveling to area’s with certain risks for infection and who are considered by a (local) government or (public) health organization at risk of being infected, and/or any other persons who may be asymptomatic at the time of testing but have a higher risk of being positive, like persons who have been identified as a result of source- and contact research.
A second collection site at the second collection hub may be arranged to obtain test samples from patients who do not fall within one of the categories of patients of whom a test sample is to be obtained at the first collection site.
As an even further option, the method further comprises obtaining laboratory capacity data from a capacity database and based on the laboratory capacity data, one of testing the first test sample and the second test sample at a first laboratory, testing the first test sample and the second test sample at a second laboratory, or testing the first test sample at a first laboratory and the second test sample at a second laboratory.
A particular laboratory may have a particular testing capacity, which may be expressed as a number of diagnostic tests per time unit, for example per hour or per day, and/or as a number of diagnostic tests which can be performed within a particular time window. Testing capacity may depend on the equipment present at the laboratory, the amount of required testing supplies in stock, and/or the number of personnel available.
Equipment may for example be a system for sample preparation, a system for pooling samples, and/or a system for performing polymerase chain reaction (PCR). Required supplies may for example be samples containers and substances required to perform at least part of the diagnostic tests such as a primer or a DNA polymerase.
In particular, the capacity database may be stored on an electronic memory device, and the obtaining of the laboratory capacity data may be performed by an electronic computer device.
The laboratory capacity data may be indicative of at least one of a testing capacity of a particular laboratory and an amount of required testing supplies present at a particular laboratory.
Embodiments of the method may further comprise, based on the obtained prevalence factor data, determining a maximum potential number of tests required for testing the first test sample and the second test sample, and determining the first laboratory and the second laboratory based on the determined maximum potential number of tests required and the obtained laboratory capacity data.
The pooling of test samples may require additional time, operator capacity, supplies and/or equipment at a particular laboratory. The laboratory capacity database may also be queried for this information. If the query results in a particular laboratory having sufficient diagnostic test capacity but insufficient pooling capacity, a different laboratory may be chosen to perform the pooling and testing of the pooled sample.
The laboratory capacity data may be updated after the third test sample or any other pooled sample is tested positive. A positive test result implies that more tests have to be performed, and hence the capacity of a particular laboratory may decrease.
Embodiments of the method may further comprise, based on the obtained prevalence factor data, determining a maximum potential number of tests required for testing the first test sample and the second test sample. Such embodiments may even further comprise determining the first laboratory and the second laboratory based on the determined maximum potential number of tests required and the obtained laboratory capacity data. When a pooled sample 1s tested positive, additional test are required to determine which of the individual test samples which formed the pooled sample were positive. As such, additional tests may be required, and a particular laboratory may be chosen to perform the pooled test based on the maximum potential number of tests required. If six test samples are pooled, the pooled test is the first test to be performed, and after a positive pooled test a maximum of six individual additional tests are required. Hence, a test capacity of seven tests may be preferred. In particular, determining a maximum potential number of tests required for testing the first test sample and the second test sample may comprise based on the obtained prevalence factor data, determining whether to pool the first test sample and the second test sample, if the first test sample and the second test sample are pooled together, determining that the maximum potential number of tests required equals one plus the total number of pooled test samples combined into the pooled sample, and if the first test sample and the second test sample are not pooled together, determining that the maximum potential number of tests equals the number of test samples combined into the pooled sample. The laboratory capacity data may comprise pooling capacity data. The pooling of test samples may require additional time, operator capacity,
supplies and/or equipment at a particular laboratory. The laboratory capacity database may also be queried for this information. If the query results in a particular laboratory having sufficient diagnostic test capacity but insufficient pooling capacity, a different laboratory may be chosen to perform the pooling and testing of the pooled sample.
When the first test sample and the second test sample are obtained at a first collection site, the method may further comprise placing the first test sample and the second test sample in a first transportation container arranged for holding a plurality of test samples, and providing the first transportation container with a first indicator indicative of the first collection site.
A transportation container may for example be a box, crate, or any other suitable container for arranged for holding a plurality of test samples. Even a transportation vehicle such as a van or truck may be considered as a transportation container. The plurality of test samples held in a transportation container can be transported together, for example from a collection site to a laboratory.
In examples, the prevalence factor of each sample in the plurality of samples held in a single transportation container may be the same. This may for example be the case when the prevalence factor depends on the prevalence factor of the collection site at which the samples are obtained.
A first indicator indicative of the first collection site may be provided to the first transportation container prior to transporting the first transportation container to the first laboratory. An indicator may for example be a marking, sticker, tag, barcode, or any other type of indicator which may for example be machine-readable. Based on the first indicator, for example at the laboratory or at the collection site, the prevalence database may be queried and/or the prevalence factor for the samples in the transportation container may be determined. Additionally or alternatively, individual test samples may be provided with a second indicator indicative of the first collection site.
The number of samples in a sample container may be counted. Based on the counted number of samples present in a sample container, for example a supply database of the first collection site may be updated and/or laboratory capacity data for the first laboratory in a capacity database may be updated.
By updating the supply database based on the counted number of samples, the amount of supplies left in stock at a particular collection site may be updated. If the stock falls below a particular threshold, new supplies may be sent out to the collection site. Examples of supplies preferred to be in stock at a collection site may be sample containers, transportation containers, swabs, sample trays, and/or safety bags.
When the number of obtained test samples is counted at a collection site, this counted number may be used for planning the transportation of the test samples. Furthermore, before transportation, using at least one of the prevalence data and laboratory capacity data, the particular laboratory to which the test samples have to be sent may be determined. Once this laboratory has been determined, a fleet planning system may be updated accordingly. Furthermore, the determined laboratory may be informed of the number of counted test samples, and optionally whether the test samples have to be pooled. As an even further option, a transportation time may be calculated for transporting the test samples from the collection site to the laboratory, and the laboratory may be informed of an estimated time of arrival of the test samples.
The counted number of obtained test samples may additionally or alternatively be used for real-time or near real-time planning of diagnostic tests to be performed at one or more laboratories, for determining a required testing capacity for one or more laboratories, for example at a particular moment in time. Even further additionally or alternatively, the counted number of obtained test samples may be used to determine at which laboratory or laboratories to perform the diagnostic tests on the test samples. Based on the counted number and optionally at least part of the prevalence data, it may be determined, for example by an electronic computer device, that a first laboratory has insufficient capacity, and that the test samples should be tested at a second laboratory which has sufficient capacity.
By updating the laboratory capacity data for the first laboratory in the capacity database after counting the number of samples in the first transportation container, the laboratory capacity data may be updated even before the first transportation container has arrived at the first laboratory. Alternatively or additionally, the counted number may be communicated to the first laboratory. As such, preparatory work and/or planning may be performed for example prior to the first transportation container arriving at the first laboratory.
The counted number of test samples in the first transportation container may be used to select the first laboratory from a plurality of laboratories together with the laboratory capacity data.
Counting of the number of test samples in a transportation container may be performed at a collection site, at a laboratory, and/or during transportation. A transportation container may be provided with an indicator indicative of the counted number or test samples at the collection site. The number of test samples in a transportation container may be counted again at a laboratory, and this counted number may be checked for correspondence with the counted number of test samples indicated by the indicator. If there 1s a discrepancy, the laboratory capacity data and/or the supply database may be updated accordingly.
It will be understood that optional features disclosed in conjunction with any embodiment of the method may be readily applied to other embodiments of the method.
BRIEF DESCRIPTION OF THE FIGURES In the figures, Fig. 1 schematically depicts a country as an example of a geographical area in which a plurality of diagnostic tests has to performed.
DETAILED DESCPRIPTION Fig. 1 schematically depicts a country 100 as an example of a geographical area in which a plurality of diagnostic tests has to performed. Present in the country 100 at a first geographical location 101 is a first collection hub 102 with a first collection site 104 and a second collection site
106. At a second geographical location 103, a third collection site 108 is present. Also present is a first laboratory 110, a second laboratory 112, and a third laboratory 114 which may as an option be provided respectively at a third geographical location, a fourth geographical location and a fifth geographical location. At each collection site, a plurality of test samples may be obtained. For example, at a given time period such as a day, 20 test samples are obtained at the first collection site 104, 40 test samples are obtained at the second collection site 106, and 100 test samples are obtained at the third collection site 108. A prevalence database of the country 100 may comprise the following data: first geographical location 101 For the test samples obtained at the first collection site 104 and the second collection site 106, based on the associated prevalence factor, it may be determined to test each test sample individually since the prevalence factor is high. For the test samples obtained at the third collection site 108, based on the associated prevalence factor, it may be determined to pool test samples together. For example, when using pools of 6 test samples, the 100 test samples may be pooled in to 16 pools of 6 samples, and 1 pool of 4 samples.
To determine at which laboratory to perform the diagnostic tests, laboratory capacity data in a capacity database may be used. The capacity database may comprise the following data, or at least part of the following data: tlm 0050 The test capacity of a particular laboratory may be indicative of the number of tests which may be conducted in a particular time window, for example the present day or the next day.
Since it has been determined that the test samples obtained at the first collection site 104 and the second collection site 106 have to be tested individually, based on the laboratory capacity data, it may be determined to test these samples at either one of the first laboratory 110, second laboratory 112, and the third laboratory 114.
For the test samples obtained at the third collection site 108, based on the prevalence data, 1t has been determined to pool the samples. Based on the example that pools of 6 test samples are to be used, it may be determined that the maximum potential number of tests required to test all test samples obtained at the third collection site equals 17+100 = 117. This number 1s calculated by observing that 17 tests have to be performed to test all pools, and that if all 17 pooled tests have a positive result, that is required to individually test all 100 test samples to confirm which test samples are positive.
Now, based on the laboratory capacity data, it may be determined to test the test samples obtained at the third collection site 108 at the second laboratory 112, since it is the only laboratory with sufficient pooling capacity and testing capacity to perform the maximum potential number of tests required to test all test samples obtained at the third collection site 108. After having tested test samples, the prevalence database may be updated. For example, if the positivity rate found in the test samples obtained at the first collection hub 102 are indicative of a low prevalence, the prevalence factor for the first geographical area may be changed from high to low.
As an option, for example at the third collection site 108, the obtained test samples may be placed in one or more transportation containers. Furthermore, as an option, the number of obtained test samples may be counted. After determining at which laboratory or laboratories the test samples are to be tested, the capacity data may be updated accordingly. For example, after determining to perform 17 pooled tests at the third laboratory 114, the pooling capacity and test capacity of the third laboratory 114 may be reduced by 17.
As an option, the test capacity may be further reduced with the maximum potential number of tests required to test all test samples. When it 1s determined that a pooled sample tests negative, this reduction may be reversed since the test capacity for testing the individual test samples in a pooled sample is no longer required.
The number of obtained test samples may further be used to update a supply database of a particular collection site or collection hub. For example, for the first collection hub, supply data in the supply database may indicate that sufficient supplies are in stock for collecting 150 test samples. After obtaining the 20 test samples at the first collection site and the 40 test samples at the second collection site, the number of collected test samples may be counted. Based on the counted number, the supply database may be updated that now sufficient supplies are in stock for collecting 150-20-40=90 test samples.
If a stock threshold of 100 is used, it may now be determined that insufficient supplies are in stock at the first collection hub 102. A new set of supplies may be dispatched to the first collection hub 102 to restock above the stock threshold.
Transporting test samples and/or transportation containers between collection sites and laboratories may be governed by a fleet management system. The fleet management system may be arranged for governing a plurality of drivers and/or transportation vehicles, and output which driver and/or transportation vehicle should be present at which location at what time, optionally with which transportation capacity. The fleet management system may comprise an electronic processing device for calculating fleet instructions which are to be executed by the drivers and/or transportation vehicles.
The fleet management system may be arranged to calculate an optimum or near optimum distribution of transportation vehicles and/or drivers over a particular geographical area based on the prevalence data and/or an expected number of tests samples to be obtained at particular collection sites. The fleet management system may be fed with real-time or near real-time information on the location of one or more of the transportation vehicle and/or drivers.
The fleet management system may for example be arranged to calculate transportation times between particular collection sites and laboratories. A decision to perform diagnostic tests at a particular laboratory may be based on the calculated transportation times. In examples, although a first laboratory may have sufficient capacity based on the laboratory capacity database, it may be decided, for example by an electronic computer device, to test the test samples at a second laboratory based on the calculated transportation times.
The fleet management system may be arranged to access the prevalence database. Based on the accessed prevalence data, the fleet management system may decide to redistribute transportation vehicles and/or drivers over a geographical area. For example, when the prevalence factor of a particular geographical area increases, it may be decided to increase the presence of transportation vehicles and/or drivers in said area, for example in anticipation of an increase in number of test samples to be obtained in said area.
It is to be noted that the figures are only schematic representations of embodiments of the invention that are given by way of non-limiting examples. For the purpose of clarity and a concise description, features are described herein as part of the same or separate embodiments, however, it will be appreciated that the scope of the invention may include embodiments having combinations of all or some of the features described.
The word ‘comprising’ does not exclude the presence of other features or steps than those listed in a claim. Furthermore, the words 'a' and 'an' shall not be construed as limited to 'only one’, but instead are used to mean 'at least one’, and do not exclude a plurality.
A person skilled in the art will readily appreciate that various parameters and values thereof disclosed in the description may be modified and that various embodiments disclosed and/or claimed may be combined without departing from the scope of the invention.

Claims (17)

ConclusiesConclusions 1. Werkwijze voor uitvoeren van een veelvoud aan diagnostische tests, omvattende: - verkrijgen van een eerste testmonster van een eerste patiént; - verkrijgen van een tweede testmonster van een tweede patiënt; - verkrijgen van, uit een prevalentiedatabase omvattende prevalentiefactordata, een eerste prevalentiefactor voor het eerste testmonster en een tweede prevalentiefactor voor het tweede testmonster; en - gebaseerd op de eerste prevalentiefactor en de tweede prevalentiefactor, één van: - individueel testen van het eerste testmonster en het tweede testmonster; of - combineren van de twee testmonsters tot een derde testmonster en testen van het derde testmonster als een samengesteld monster.A method for performing a plurality of diagnostic tests, comprising: - obtaining a first test sample from a first patient; - obtaining a second test sample from a second patient; - obtaining, from a prevalence database comprising prevalence factor data, a first prevalence factor for the first test sample and a second prevalence factor for the second test sample; and - based on the first prevalence factor and the second prevalence factor, one of: - individually testing the first test sample and the second test sample; or - combining the two test samples into a third test sample and testing the third test sample as a composite sample. 2. Werkwijze volgens conclusie 1, verder omvattende wanneer het eerste testmonster en het tweede testmonster individueel getest zijn, bepalen welke van het eerste testmonster en het tweede testmonster als eerste getest moet worden gebaseerd op de eerste prevalentiefactor en de tweede prevalentiefactor.The method of claim 1, further comprising when the first test sample and the second test sample are individually tested, determining which of the first test sample and the second test sample should be tested first based on the first prevalence factor and the second prevalence factor. 3. Werkwijze volgens conclusie 1 of 2, waarin de prevalentiedatabase is opgeslagen op een elektronische geheugenapparaat, en het verkrijgen van de eerste prevalentiefactor en de tweede prevalentiefactor gedaan wordt door een elektronische computerapparaat.The method of claim 1 or 2, wherein the prevalence database is stored on an electronic memory device, and obtaining the first prevalence factor and the second prevalence factor is done by an electronic computing device. 4. Werkwijze volgens een van de voorgaande conclusies, waarin, wanneer de eerste prevalentiefactor en de tweede prevalentiefactor allebei beneden een vooraf bepaalde prevalentiefactordrempelwaarde zijn, de twee testmonsters gecombineerd worden tot een derde testmonster en het derde testmonster getest wordt als een samengesteld monster.The method of any preceding claim, wherein when the first prevalence factor and the second prevalence factor are both below a predetermined prevalence factor threshold, the two test samples are combined into a third test sample and the third test sample is tested as a composite sample. 5. Werkwijze volgens een van de voorgaande conclusies, verder omvattende updaten van de prevalentiedatabase gebaseerd op de testresultaten van het eerste testmonster en/of het tweede testmonster en/of het derde testmonster.A method according to any preceding claim, further comprising updating the prevalence database based on the test results of the first test sample and/or the second test sample and/or the third test sample. 6. Werkwijze volgens een van de voorgaande conclusies, waarin: - het eerste testmonster verkregen wordt op een eerste verzamellocatie;A method according to any one of the preceding claims, wherein: - the first test sample is obtained at a first collection location; - het tweede testmonster verkregen wordt op een tweede verzamellocatie; en de prevalentiefactordata prevalentiedata omvat voor de eerste verzamellocatie en de tweede verzamellocatie.- the second test sample is obtained at a second collection location; and the prevalence factor data includes prevalence data for the first collection location and the second collection location. 7. Werkwijze volgens een van de voorgaande conclusies, verder omvattende: - verkrijgen van laboratoriumcapaciteitsdata uit een capaciteitsdatabase; en - gebaseerd op de laboratoriumcapaciteitsdata, één van: 0 testen van het eerste testmonster en het tweede testmonster in een eerste laboratorium; o testen van het eerste testmonster en het tweede testmonster in een tweede laboratorium; of 0 testen van het eerste testmonster in het eerste laboratorium en het tweede testmonster in het tweede laboratorium.Method according to one of the preceding claims, further comprising: - obtaining laboratory capacity data from a capacity database; and - based on the laboratory capability data, one of: 0 testing the first test sample and the second test sample in a first laboratory; o testing the first test sample and the second test sample in a second laboratory; or 0 testing the first test sample in the first lab and the second test sample in the second lab. 8. Werkwijze volgens conclusie 7, waarin de capaciteitsdatabase opgeslagen is op een elektronisch geheugenapparaat, en het verkrijgen van laboratoriumcapaciteitsdata uitgevoerd wordt door een elektronisch computerapparaat.The method of claim 7, wherein the capability database is stored on an electronic memory device, and the acquisition of laboratory capability data is performed by an electronic computing device. 9. Werkwijze volgens conclusie 7 of 8, waarin de laboratoriumcapaeiteitsdata indicatief is voor ten minste een van een testcapaciteit van een bepaald laboratorium en een hoeveelheid benodigde testbenodigdheden aanwezig bij een bepaald laboratorium.The method of claim 7 or 8, wherein the laboratory capacity data is indicative of at least one of a test capacity of a particular laboratory and an amount of required test supplies present at a particular laboratory. 10. Werkwijze volgens een van de conclusies 7-9, verder omvattende: - gebaseerd op de verkregen prevalentiefactordata, bepalen van een maximale potentiele hoeveelheid tests benodigd voor het testen van het eerste testmonster en het tweede testmonster; en - bepalen van het eerste laboratorium en het tweede laboratorium gebaseerd op de maximale potentiele hoeveelheid tests benodigd en de verkregen laboratoriumcapaciteitsdata.A method according to any one of claims 7-9, further comprising: - based on the obtained prevalence factor data, determining a maximum potential amount of tests required for testing the first test sample and the second test sample; and - determining the first laboratory and the second laboratory based on the maximum potential amount of tests required and the obtained laboratory capacity data. 11. Werkwijze volgens een van de conclusies 7-10, waarin wanneer een van het eerste, tweede, en/of derde testmonster positief test, de werkwijze verder updaten omvat van de laboratoriumcapaciteitsdata gebaseerd op het positieve testresultaat van de ene van het eerste, tweede, en/of derde testmonster.The method of any one of claims 7-10, wherein when one of the first, second, and/or third test samples tests positive, the method further comprises updating the laboratory capability data based on the positive test result of the one of the first, second , and/or third test sample. 12. Werkwijze volgens een van de conclusies 7-11, verder omvattende: - gebaseerd op de verkregen prevalentiefactordata, bepalen van een maximale potentiele hoeveelheid tests benodigd voor het testen van het eerste testmonster en het tweede testmonster; en - bepalen van het eerste laboratorium en het tweede laboratorium gebaseerd op de maximale potentiele hoeveelheid tests benodigd en de verkregen laboratoriumeapaciteitsdata.A method according to any one of claims 7-11, further comprising: - based on the obtained prevalence factor data, determining a maximum potential amount of tests required for testing the first test sample and the second test sample; and - determining the first laboratory and the second laboratory based on the maximum potential amount of tests needed and the obtained laboratory capacity data. 13. Werkwijze volgens conclusie 12, waarin bepalen van een maximale potentiele hoeveelheid tests benodigd voor het testen van het eerste testmonster en het tweede testmonster omvat: - gebaseerd op de verkregen prevalentiefactordata, bepalen of het eerste testmonster en het tweede testmonster gecombineerd moeten worden; - als het eerste testmonster en het tweede testmonster gecombineerd zijn, bepalen dat de maximale potentiele hoeveelheid tests benodigd gelijk is aan één plus het totaal aantal gecombineerde testmonsters welke gecombineerd zijn in het samengestelde monster; en - als het eerste testmonster en het tweede testmonster niet gecombineerd worden, bepalen dat de maximale potentiele hoeveelheid tests benodigd gelijk is aan het aantal testmonsters welke gecombineerd zijn in het samengestelde monster.The method of claim 12, wherein determining a maximum potential amount of tests needed to test the first test sample and the second test sample comprises: - based on the obtained prevalence factor data, determining whether the first test sample and the second test sample should be combined; - if the first test sample and the second test sample are combined, determine that the maximum potential amount of tests needed is equal to one plus the total number of combined test samples combined in the composite sample; and - if the first test sample and the second test sample are not combined, determining that the maximum potential amount of tests needed is equal to the number of test samples combined in the composite sample. 14. Werkwijze volgens een van de conclusies 1-5, waarin het eerste testmonster en het tweede testmonster verkregen worden op een eerste verzamellocatie, de werkwijze verder omvattende: - plaatsen van het eerste testmonster en het tweede testmonster in een eerste transportcontainer welke is ingericht voor houden van een veelvoud aan testmonsters; en - voorzien van de eerste transportcontainer met een eerste markering indicatief voor de eerste verzamellocatie.A method according to any one of claims 1-5, wherein the first test sample and the second test sample are obtained at a first collection location, the method further comprising: - placing the first test sample and the second test sample in a first transport container arranged for holding a plurality of test samples; and - provided with the first transport container with a first marking indicative of the first collection location. 15. Werkwijze volgens conclusie 14, verder omvattende: - tellen van het aantal testmonsters in de eerste monstercontainer; en tenminste één van:The method of claim 14, further comprising: - counting the number of test samples in the first sample container; and at least one of: - updaten van een voorraadsdatabase van de eerste verzamellocatie gebaseerd op het getelde aantal testmonsters; en - updaten van laboratoriumcapaciteitsdata van het eerste laboratorium in de capaciteitsdatabase op basis van het getelde aantal testmonsters.- updating an inventory database of the first collection location based on the counted number of test samples; and - updating laboratory capacity data of the first laboratory in the capacity database based on the counted number of test samples. 16. Werkwijze volgens conclusie 14 of 15, verder omvattende: - tellen van het aantal testmonsters in de eerste monstercontainer; - verkrijgen van laboratoriumcapaciteitsdata uit een capaciteitsdatabase; - selecteren van het eerste laboratorium uit een veelvoud van laboratoria gebaseerd op de laboratoriumcapaciteitsdata en het getelde aantal testmonsters.A method according to claim 14 or 15, further comprising: - counting the number of test samples in the first sample container; - obtaining laboratory capacity data from a capacity database; - selecting the first laboratory from a plurality of laboratories based on the laboratory capacity data and the counted number of test samples. 17. Werkwijze volgens conclusie 16, waarin selecteren van het eerste laboratorium verder gebaseerd is op een bepaalde maximale potentiele hoeveelheid tests benodigd voor testen van de testmonsters in de eerste transportcontainer.The method of claim 16, wherein selecting the first laboratory is further based on a determined maximum potential amount of tests needed to test the test samples in the first shipping container.
NL2026445A 2020-09-10 2020-09-10 Method for performing a plurality of diagnostic tests NL2026445B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL2026445A NL2026445B1 (en) 2020-09-10 2020-09-10 Method for performing a plurality of diagnostic tests

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2026445A NL2026445B1 (en) 2020-09-10 2020-09-10 Method for performing a plurality of diagnostic tests

Publications (1)

Publication Number Publication Date
NL2026445B1 true NL2026445B1 (en) 2022-05-09

Family

ID=73402042

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2026445A NL2026445B1 (en) 2020-09-10 2020-09-10 Method for performing a plurality of diagnostic tests

Country Status (1)

Country Link
NL (1) NL2026445B1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3670669A1 (en) * 2020-03-24 2020-06-24 DRK-Blutspendedienst Baden-Württemberg - Hessen gemeinnützige GmbH Detection of sars-cov-2 in a plurality of biological samples

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3670669A1 (en) * 2020-03-24 2020-06-24 DRK-Blutspendedienst Baden-Württemberg - Hessen gemeinnützige GmbH Detection of sars-cov-2 in a plurality of biological samples

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABDALHAMID BAHA ET AL: "Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 153, no. 6, 5 May 2020 (2020-05-05), US, pages 715 - 718, XP055801016, ISSN: 0002-9173, DOI: 10.1093/ajcp/aqaa064 *
KHAI LONE LIM ET AL: "A novel strategy for community screening of SARS-CoV-2 (COVID-19): Sample pooling method", 28 August 2020 (2020-08-28), XP055800886, Retrieved from the Internet <URL:https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pone.0238417/1/pone.0238417.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa@plos-prod.iam.gserviceaccount.com/20210503/auto/storage/goog4_request&X-Goog-Date=20210503T132542Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=ho> [retrieved on 20210503], DOI: https://doi.org/10.1371/journal.pone.0238417 *
REGEN FRANCESCA ET AL: "A simple approach to optimum pool size for pooled SARS-CoV-2 testing", INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES, HAMILTON, CA, vol. 100, 28 August 2020 (2020-08-28), pages 324 - 326, XP086345182, ISSN: 1201-9712, [retrieved on 20200828], DOI: 10.1016/J.IJID.2020.08.063 *
RUDOLF HANEL ET AL: "Boosting test-efficiency by pooled testing strategies for SARS-CoV-2", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 22 March 2020 (2020-03-22), XP081627062 *

Similar Documents

Publication Publication Date Title
Jarvis Improving emergency department patient flow
Park et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006
Skoglund et al. Estimated clinical and economic impact through use of a novel blood collection device to reduce blood culture contamination in the emergency department: a cost-benefit analysis
Lerner Studies Evaluating current field triage: 1966—2005
Manor Turnaround times in the laboratory: a review of the literature
Duydu et al. Assessment of DNA integrity (COMET assay) in sperm cells of boron-exposed workers
CN110391018A (en) Analyzing timely availability of test results
Cullen et al. Growth variability, dimensional scaling, and the interpretation of osteohistological growth data
Vodicka et al. Costs of integrating cervical cancer screening at an HIV clinic in Kenya
Vuk et al. Error management in blood establishments: results of eight years of experience (2003–2010) at the Croatian Institute of Transfusion Medicine
Viviani et al. Male and female fertility: prevention and monitoring Hodgkin’lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi
Scott et al. The development of a machine learning algorithm to identify occupational injuries in agriculture using pre-hospital care reports
NL2026445B1 (en) Method for performing a plurality of diagnostic tests
Luchristt et al. Risk of obstetric anal sphincter injuries at the time of admission for delivery: a clinical prediction model
Jensen et al. Alternatives to traditional EMS dispatch and transport: a scoping review of reported outcomes
Naides Establishing a Pregnancy Lyme Disease Biobank
Xiang et al. Application of unsupervised machine learning to identify areas of blood product wastage in transfusion medicine
Sharma et al. Australian donation and transplantation biobank: a research biobank integrated within a deceased organ and tissue donation program
Knepper et al. Time-saving impact of an algorithm to identify potential surgical site infections
Klontz et al. Cerebrospinal fluid metagenomics has greatest added value as a test for Powassan virus among patients in New England with suspected central nervous system infection
Young et al. Urban-rural differences in work disability after an occupational injury
Lockhart et al. Intersection of biobanking and clinical care: should discrepant diagnoses and pathological findings be returned to research participants?
Wong et al. Door-in-door-out times for patients with large vessel occlusion ischaemic stroke being transferred for endovascular thrombectomy: a Victorian state-wide study
Barros-Sierra et al. SARS-CoV-2 seroprevalence and respiratory disease disability claims in Mexico City Metropolitan Area
Gavin et al. Accuracy of the simplified HOSPITAL score in predicting COVID-19 readmissions—exploring outcomes from a hospital-at-home program

Legal Events

Date Code Title Description
MM Lapsed because of non-payment of the annual fee

Effective date: 20231001